BGA
ALNY icon

Belmont Global Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Belmont Global Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.02M Buy
+15,000
New +$1.06M 0.96% 22
2014
Q3 		– Sell
-6,500
Closed -$411K – 123
2014
Q2 		$411K Buy
+6,500
New +$386K 0.3% 86

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Belmont Global Advisors's ALNY Position: Q3 2016 in Review

Belmont Global Advisors opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2016: 15,000 shares worth $1.02M. The stake represents 0.96% of the portfolio and ranks #22 among its holdings. This is a return to the name: Belmont Global Advisors previously reported a position in ALNY as recently as Q2 2014.

Belmont Global Advisors first reported a position in ALNY in Q2 2014 and has held it in 2 quarters since. 258 funds tracked by Wall St. Rank hold ALNY as of Q3 2016.

  • Belmont Global Advisors held 15,000 shares of Alnylam Pharmaceuticals worth $1.02M as of Q3 2016.
  • Alnylam Pharmaceuticals was a new Belmont Global Advisors position in Q3 2016.
  • Alnylam Pharmaceuticals made up 0.96% of Belmont Global Advisors's portfolio in Q3 2016, its #22 holding.
  • Belmont Global Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2014 and has held it in 2 quarters since.
  • 258 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2016.

Based on Belmont Global Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.